Mode
Text Size
Log in / Sign up
N/A N=34 Triple-blind Other

A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects

Erythema · Edema

Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcome: Primary: Number of Subjects With Observed Local Erythema Based on 5 Point Scale — 0 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Trojan "Simply Pleasure" Personal Lubricant (Device)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Church & Dwight Company, Inc.
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Observed Local Erythema Based on 5 Point Scale
PRIMARY
Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale

Summary

To evaluate the safety of a personal lubricant when used at least four times weekly for two weeks (including at least twice weekly during sexual intercourse for subjects with monogamous male partners), in a population consisting of healthy females.

Eligibility Criteria

Inclusion Criteria

  • no participation in a similar study 2-weeks prior
  • may be post-menopausal or have had a hysterectomy
  • if sexually active, and of child bearing potential, subjects is using adequate non-barrier method of birth control
  • free from any vaginal disorders
  • sexually active and in a monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the two-week study or is not sexually active
  • personal lubricant user and agrees to replace her usual personal lubricant with the investigational product
  • can start regardless of where they are in their cycles
  • agrees to use the provided investigational product at least four time weekly over the two week study period
  • exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline exam
  • willing to refrain from introducing any new vaginal products, or using vaginal medications or local contraceptives during study
  • agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area
  • willing to use a urine pregnancy test provided to them at baseline and on third visit
  • standard medical history form on file
  • signed informed consent
  • completed HIPAA
  • dependable and able to follow directions as outlined
  • receives a score of 0 or 0.5 for erythema and edema; and 0 for sensorial irritation (burning, stinging, itching and dryness) during the first examination.

Exclusion Criteria

  • pregnant, nursing or planning a pregnancy
  • currently using or has used within two weeks prior to the study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, anti-inflammatories or antihistamines
  • known allergies to vaginal or any cosmetic products
  • reports history of recurrent bladder, vaginal infections or incontinence
  • exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days prior to study initiation
  • uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception
  • participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation
  • receives a score higher than 0/5 for erythema, edema or >0 for burning, stinging, or itching, during first examination or shows any other sign of mucosal irregularities
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02737592). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search